Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:39 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Insomnia Prevalence and Treatment Impact on Systemic Hypertension
NCT05414864 · University of Sao Paulo · PHASE4 · terminated · last registry update 2022-12-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Takeda suspended financial support. The first phase (observational study) is ongoing.” | – | Registry record, University of Sao Paulo |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MTNR1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-12-19Results posted on the registry: Rush University Medical Center, a drug against MTNR1A (NCT02373189)
- 2023-11-13Results posted on the registry: Brigham and Women's Hospital, a drug against MTNR1A (NCT01863446)
- 2023-10-26Phase 3 first posted: University of Jordan, Placebo + Diazepam (NCT06103188)
- 2023-10-13Results posted on the registry: Amy Gelfand, Melatonin + Placebo oral capsule (NCT03150797)
- 2023-10-13Also stopped (terminated): Amy Gelfand, Melatonin + Placebo oral capsule (NCT03150797)
- 2023-10-02Phase 3 first posted: Lone Baandrup, Melatonin + Quetiapine (NCT06062953)
- 2023-09-15Results posted on the registry: Vanda Pharmaceuticals, Tasimelteon + Placebo (NCT03373201)
- 2023-09-08Also stopped (terminated): University of Nebraska, Natrol (NCT01033565)
- 2023-07-20Also stopped (withdrawn): AGUNCO Obstetrics and Gynecology Centre, Recombinant FSH (rFSH) (NCT01267604)
- 2023-05-30Also stopped (terminated): Rockefeller University, a drug against MTNR1A (NCT02732288)
- 2023-05-12Phase 3 first posted: Coordinación de Investigación en Salud, Mexico, Melatonin 10 MG (NCT05857046)
- 2023-04-04Results posted on the registry: University of Nebraska, a drug against MTNR1A (NCT03730194)
- 2023-03-30Results posted on the registry: Virginia Commonwealth University, Melatonin + Placebo (NCT02332928)
- 2023-03-30Also stopped (terminated): Virginia Commonwealth University, Melatonin + Placebo (NCT02332928)
- 2022-12-22Also stopped (terminated): University of Michigan, a drug against MTNR1A (NCT02940769)
- 2022-12-15Phase 3 first posted: Monash University, Melatonin 10 MG (NCT05651347)
- 2022-11-25Results posted on the registry: University of Michigan, Melatonin 0.5 MG (NCT03715465)
- 2022-10-06Phase 3 first posted: Ain Shams University, a drug against MTNR1A (NCT05570526)
- 2022-09-15Phase 3 first posted: Arash Afshari, Melatonin + Isotonic sodium chloride solution (NCT05541276)
- 2022-09-13Phase 3 first posted: Universitat Internacional de Catalunya, Melatonin 10 MG Oral Tablet + Hydroxycobalamin (NCT05536596)
- 2022-08-16Phase 3 first posted: Gustav Stalhammar, Melatonin (NCT05502900)
- 2022-07-26Phase 3 first posted: M.D. Anderson Cancer Center, Melatonin + Melatonin (NCT05474846)
- 2022-07-22Also stopped (withdrawn): State University of New York at Buffalo, Melatonin + Placebo (NCT04784754)
- 2022-07-14Also stopped (withdrawn): Institution de Lavigny, melatonin + placebo (NCT01370486)
- 2022-06-30Phase 3 first posted: National Taiwan University Hospital, Melatonin + Placebo (NCT05439876)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision